Advertisement

Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas

Hans-Peter Gerber, May Kung-Sutherland, Ivan Stone, Carol Morris-Tilden, Jamie Miyamoto, Renee McCormick, Stephen C. Alley, Nicole Okeley, Brad Hayes, Francisco J. Hernandez-Ilizaliturri, Charlotte F. McDonagh, Paul J. Carter, Dennis Benjamin and Iqbal S. Grewal

Article Information

Citation 
vol. 113 no. 18 4352-4361
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted September 17, 2008
  • Accepted December 31, 2008
  • Published online April 30, 2009.

Article Versions


Contributors 
  • Hans-Peter Gerber, Departments of 1Preclinical Therapeutics,
  • May Kung-Sutherland, Departments of 1Preclinical Therapeutics,
  • Ivan Stone, Departments of 1Preclinical Therapeutics,
  • Carol Morris-Tilden, Departments of 1Preclinical Therapeutics,
  • Jamie Miyamoto, Departments of 1Preclinical Therapeutics,
  • Renee McCormick, Departments of 1Preclinical Therapeutics,
  • Stephen C. Alley, 2Chemistry, and
  • Nicole Okeley, 2Chemistry, and
  • Brad Hayes, 3Analytical Biochemistry and Formulations, Seattle Genetics, Bothell, WA;
  • Francisco J. Hernandez-Ilizaliturri, 4Departments of Medicine and Immunology, Roswell Park Cancer Institute, Buffalo, NY; and
  • Charlotte F. McDonagh, 5Department of Antibody Engineering, Seattle Genetics, Bothell, WA
  • Paul J. Carter, 5Department of Antibody Engineering, Seattle Genetics, Bothell, WA
  • Dennis Benjamin, 2Chemistry, and
  • Iqbal S. Grewal, Departments of 1Preclinical Therapeutics,

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output